Educational video combined with augmented clinical support to improve CPAP use in patients with obstructive sleep apnea-hypopnea syndrome: A randomized controlled trial protocol
Abstract
Background: Poor patient adherence to continuous positive airway pressure (CPAP) remains a common challenging issue and a major cause of treatment failure in patients with obstructive sleep apnea-hypopnea syndrome (OSAHS). Our study aims to test the hypothesis that therapeutic patient education (TPE) combined with augmented clinical support (ACS) at CPAP initiation would improve CPAP adherence and treatment outcomes compared to usual care.
Patients and methods: We will perform a prospective, randomized, controlled, parallel-group trial including 60 adult patients newly diagnosed with severe OSAHS. Each patient will be randomly assigned to either the TPE group or the usual care group and then scheduled to start CPAP therapy within 1-2 weeks after the nocturnal polygraph recording. For the TPE group, CPAP initiation will be performed at the hospital during a 3-hour educational session that will include 4 workshops entitled: "What's OSAHS", "CPAP machine: what is it? How does it work? And what does it serve for?", "How to use your CPAP and fit your mask" and "How to deal with CPAP side effects". The educational team will include a sleep disorders specialist, a sleep nurse, and a CPAP technician. As educational tools, we will use a short storytelling video in the local language, live demonstrations and a daily desk calendar with 60 removable sheets and 1 tip on CPAP therapy on each sheet. Patients assigned to the usual care group will undergo CPAP initiation at home under the…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 60 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.